Home Cart Sign in  
Chemical Structure| 957135-43-2 Chemical Structure| 957135-43-2

Structure of SM-164
CAS No.: 957135-43-2

Chemical Structure| 957135-43-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SM-164 is a cell-permeable Smac mimetic compound that binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM, functioning as an extremely potent XIAP antagonist.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SM-164

CAS No. :957135-43-2
Formula : C62H84N14O6
M.W : 1121.42
SMILES Code : C[C@H](NC)C(N[C@H]1CCCC[C@](CC[C@H]2C(N[C@@H](C3=CC=CC=C3)C4=CN(CCCCC5=CC=C(CCCCN6N=NC([C@@H](NC([C@@H]7CC[C@@](CCCC[C@@H]8NC([C@@H](NC)C)=O)([H])N7C8=O)=O)C9=CC=CC=C9)=C6)C=C5)N=N4)=O)([H])N2C1=O)=O
MDL No. :MFCD28167763
InChI Key :LGYDZXNSSLRFJS-IOQQVAQYSA-N
Pubchem ID :17756618

Safety of SM-164

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
bone-marrow-derived macrophages (BMDMs) 50 nM to 5 µM 4 hours to 24 hours SM-164 induces macrophage death by degrading cIAP1 and cIAP2, with the mechanism being prograμMed necrosis (necroptosis). PMC3469059
MDA-MB-231 breast cancer cells 1 nmol/L 12 hours induced 32% of the cells to undergo apoptosis PMC2784911
SK-OV-3 ovarian cancer cells 1 nmol/L 12 hours induced 33% of the cells to undergo apoptosis PMC2784911
MALME-3M melanoma cells 1 nmol/L 12 hours induced 37% of the cells to undergo apoptosis PMC2784911
MDA-MB-231 5 nM 16 hours To evaluate the effect of SM-164 on apoptosis, results showed that SM-164 induced cleavage of caspase-3 and PARP, indicating apoptosis. PMC3294058
SKOV-3 5 nM 16 hours To evaluate the effect of SM-164 on apoptosis, results showed that SM-164 induced cleavage of caspase-3 and PARP, indicating apoptosis. PMC3294058
MDA-MB-231 cells 3 nM 16 hours To evaluate the effect of SM-164 combined with LPS on the apoptosis of MDA-MB-231 cells. Results showed that SM-164 combined with LPS significantly increased the apoptosis rate. PMC9471085
MCF7 cells 3 nM 16 hours To evaluate the effect of SM-164 combined with LPS on the apoptosis of MCF7 cells. Results showed that SM-164 combined with LPS did not significantly increase the apoptosis rate, but combined with TNFα, it induced apoptosis. PMC9471085
MDA-MB-231 cells 3 nM 24 hours SM-164 alone slightly but significantly increased the percentage of early and late apoptosis and dead cells in MDA-MB-231 cells, but when combined with the conditioned medium from M-DCsTNF, it significantly induced cell apoptosis and death. PMC11303651
UMSCC-1 10 nM or 200 nM 2 hours SM-164 showed dose-dependent radiosensitization in UMSCC-1 cells with SERs of 1.4 and 1.5, respectively. PMC3073022
UMSCC-17B 200 nM 2 hours SM-164 showed radiosensitization in UMSCC-17B cells with an SER of 1.6. PMC3073022
UMSCC-12 200 nM 2 hours SM-164 showed no significant radiosensitization in UMSCC-12 cells. PMC3073022
UMSCC-74B 200 nM 2 hours SM-164 showed no significant radiosensitization in UMSCC-74B cells. PMC3073022
MDA-MB-231 cells 3 nM overnight SM-164 in combination with TNFα induced apoptosis of MDA-MB-231 cells PMC7181667

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice intraperitoneal injection 50 mg/kg Every other day for 2 months SM-164 treatment leads to increased macrophage death in vivo and compromised control of the bacterial pathogen Listeria monocytogenes. PMC3469059
mice MDA-MB-231 xenograft tumor model intravenous injection 5 mg/kg daily for 4 days induced rapid cIAP-1 degradation and robust apoptosis in tumor tissues and achieved tumor regression PMC2784911
SCID mice MDA-MB-231 xenograft model Intravenous injection 130 mg/kg Single dose, 12 hours duration To evaluate the tumor growth inhibitory effect of SM-164 alone or in combination with GSK1363089, results showed that the combination significantly inhibited tumor growth. PMC3294058
NSG mice Breast cancer model Intraperitoneal injection 5 mg/kg single dose To evaluate the effect of SM-164 combined with LPS on tumor growth in a breast cancer mouse model. Results showed that SM-164 alone significantly inhibited tumor growth, and combined with LPS, it exhibited a stronger inhibitory effect in advanced tumors. PMC9471085
NSG mice Breast cancer bone metastasis model Intraperitoneal injection 3 mg/kg Twice daily for 4 weeks SM-164 alone had no significant effect on tumor size or weight, but when combined with M-DCsTNF, it significantly inhibited tumor growth. PMC11303651
Nude mice UMSCC-1 xenograft model Intravenous injection 200 mg/kg/day once daily for 4 weeks SM-164 significantly suppressed the growth of UMSCC-1 xenograft tumors and was well-tolerated by the animals. PMC3073022
nude mice triple-negative breast cancer metastasis to bone and lung model intraperitoneal injection 3 mg/kg Twice daily for 10 days SM-164 significantly reduced the progression of advanced bone and lung metastases from the triple-negative human breast cancer cell line, MDA-MB-231, in a mouse model PMC7181667

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.89mL

0.18mL

0.09mL

4.46mL

0.89mL

0.45mL

8.92mL

1.78mL

0.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories